KalVista Pharmaceuticals announced that the FDA postponed its regulatory decision on the company’s on-demand oral therapy for hereditary angioedema. The delay is attributed to the agency’s heavy workload and limited resources. KalVista had anticipated an approval timeline but now awaits further communication from FDA regarding next steps and potential revised schedules.